Multidiscipline Care for Acute Kidney Disease (AKD)
Status:
Recruiting
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
The incidence rate of acute kidney injury (AKI) in hospitalized patients is increasing, and
the mortality associated with dialysis-requiring AKI remains as high as 60-70%. In these
patients, AKI results are increased in-hospital and post-hospitalization medical resource
utilization. To improve AKI-associated morbidity and mortality, Taiwan Consortium of Acute
Kidney Injury and Renal Diseases (CAKS, TCTC) as the leading clinical trial group of kidney
diseases in Asia-Pacific will establish an anonymous nationwide AKI database to explore the
epidemiology, risk factors and prognosis of AKI in Taiwan. The demographic and clinical
information of AKI stage 2, 3 or weaning from dialysis requiring AKI patients (AKI-D), will
be prospectively collected for further analysis. In this double two-by-two factorial design,
upon the identification of AKI stage 2, 3 or weaning from AKI-D at index out patients
clinics, enrollees who are randomly assigned to slow kidney function progression first by
randomization to add Angiotensin-Converting Enzyme Inhibitors (ACE-I)/Angiotensin II Receptor
Blocker (ARB), or by randomization to multidisciplinary care. Patients will be followed up at
least 6 months to evaluate kidney function and the predictability of developing chronic
kidney disease, end stage renal disease, major cardiovascular events and mortality.